(MENAFN) Ranbaxy Laboratories' Ltd. CEO, Arun Sawhney, stated that the Indian drugmaker plans to expand its sales in the US, reported AP.
Sawhney said that he hopes to sell a number of brand-name drugs in the US; moreover, he has plans to launch sales of a recently approved generic version of acne drug Accutane in bout 6 months.
He added that sales in the US have grown in few years from nearly a quarter to a third of the company's total revenue, which was around USD2.1 billion in 2011.
Global sales in the first quarter surged 55 percent to almost USD736 million, driven in part by strong US sales, mainly from new generic versions of Lipitor and a combo pill containing Lipitor and blood-pressure medicine Norvasc.
It is worth noting that Ranbaxy plans to expand generic sales not only in the US, but also in emerging markets that are heavily populated with a rising middle class and increasing government spending on health care.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.